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Peroxisomeproliferator-activatedreceptors(PPARs)areligandbindingtranscriptionfactorswhichfunctioninmanyphysiological
roles including lipid metabolism, cell growth, diﬀerentiation, and apoptosis. PPARs and their ligands have been shown to play a
role in cancer. In particular, PPARγ ligands including endogenous prostaglandins and the synthetic thiazolidinediones (TZDs)
can induce apoptosis of cancer cells with antitumor activity. Thus, PPARγ ligands have a potential in both chemoprevention
and therapy of several types of cancer either as single agents or in combination with other antitumor agents. Accordingly, the
involvement of PPARγ and its ligands in regulation of apoptosis of cancer cells have been extensively studied. Depending on
cell types or ligands, induction of apoptosis in cancer cells by PPARγ ligands can be either PPARγ-dependent or -independent.
Through increasing our understanding of the mechanisms of PPARγ ligand-induced apoptosis, we can develop better strategies
which may include combining other antitumor agents for PPARγ-targeted cancer chemoprevention and therapy. This review will
highlight recent research advances on PPARγ and apoptosis in cancer.
Copyright © 2008 H. A. Elrod and S.-Y. Sun. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are lig-
and binding transcription factors belonging to the nuclear
receptor superfamily which includes receptors for steroids,
thyroid hormone, and retinoids [1, 2]. PPARs function in
a variety of roles including regulation of lipid metabolism,
immune function, cell growth, diﬀerentiation, and apoptosis
[2]. PPARs are involved in several diseases including obesity,
diabetes, cardiovascular disease, and cancer [3]. Three
diﬀerent subtypes of PPARs have been identiﬁed, PPARα,
PPARβ/δ,a n dP P A R γ, each encoded by separate genes.
The three isoforms share functions as well as have distinct
activities [2].
PPARs function by regulating gene transcription via
bindingtoDNAsequencesknownasperoxisomeproliferator
response elements (PPREs) located in the promoter regions
of target genes. PPREs are direct repeats of the consensus
sequence with a spacing of one nucleotide (AGGTCA N
AGGTCA) [4]. PPARs bind to PPREs as heterodimers with
retinoid X receptors (RXR). The heterodimer PPAR/RXR
can bind other transcriptional coactivators or corepressors
to inﬂuence gene transcription [1]. Ligand binding to PPARs
induces conformational changes that release corepressors
from the heterodimer and recruit coactivators to allow for
target gene transcription [5].
Synthetic and endogenous PPAR ligands have been used
to elucidate the role of PPARs. Speciﬁcally, thiazolidine-
diones (TZDs) including pioglitazone, ciglitazone, troglita-
zone, and rosiglitazone are synthetic PPARγ ligands which
are insulin-sensitizing agents developed to treat diabetes
mellitus [2]. The naturally occurring prostaglandin, 15-
deoxy-Δ12,14-prostaglandin J2(15d-PGJ2), is generally con-
sidered to be an endogenous PPARγ ligand [6, 7]. The
promiscuous nature of PPARs may lead to the binding of
multiple ligands resulting in the activation of many cellular
pathways. These ligands have been extensively studied and
shown to exert antineoplastic properties including induction
of apoptosis.
Apoptosis or programed cell death is a highly regulated
process critical for normal development and tissue home-
ostasis. Aberrant regulation of apoptosis can lead to cancer.
Apoptosis is induced from signals inside or outside the
cell including radiation, viral infection, growth factors, and2 PPAR Research
Table 1: PPARγ agonists induce apoptosis in cancer.
PPARγ agonist PPARγ Tumor type Molecular mediator(s) of
apoptosis Reference
15d-PGJ2 Independent Breast Unknown [8]
Troglitazone and 15d-PGJ2 Dependent Thyroid c-myc [9]
Ciglitazone Dependent Thyroid PPARγ [10]
Rosiglitazone Dependent Thyroid NF-κB, cyclinD1, caspase-3 [11]
Troglitazone and 15d-PGJ2 Unknown Colon c-myc, c-jun, GADD153 [12]
Troglitazone Dependent Lung GADD153 [13]
Troglitazone Independent Colon EGR-1, NAG-1 [14, 15]
15d-PGJ2 Dependent Colon EGR-1, NAG-1 [15]
Troglitazone Dependent Lung ERK1/2 [16]
Troglitazone Dependent and
independent Colon p53, POX [17]
Troglitazone Independent Prostate Bcl-2, Bcl-XL [18]
15d-PGJ2 Independent Oral Stat3 [19]
15d-PGJ2 Independent Prostate, bladder Caspase-3, -7 [20]
15d-PGJ2 Independent Multiple myeloma, burkitt
lymphoma
NF-kappa-B, cIAP-1, XIAP,
c-FLIP [21]
Rosiglitazone Dependent Breast PPARγ,p 5 3 [ 22]
hormones [23]. Apoptosis involves signature morphological
changes induced by caspases, which are activated upon
induction of apoptotic signaling and cleave downstream
molecules to facilitate the apoptotic cascade [24]. The
induction of apoptosis can occur through two pathways: the
intrinsicapoptoticpathwaywhichinvolvessignalingthrough
the mitochondria and the extrinsic apoptotic pathway which
is initiated through activation of cell surface death receptors
[25]. Apoptotic signaling through the intrinsic pathway
primarilyinvolvesactivationoftheproapoptoticBcl-2family
members Bax and Bak, which facilitate release of cytochome
C from the mitochondria and subsequent caspase-9 cleavage
or activation. The activated caspase-9 will ﬁnally cleave or
activate the downstream eﬀector caspases such as caspase-
3 and -7, leading to apoptosis. This pathway is negatively
regulated by several antiapoptotic Bcl-2 family members
such as Bcl-2 and Bcl-XL [26]. Apoptotic signaling through
the extrinsic pathway is initiated by ligand binding to
death receptors or by induction of trimerization of the
receptors [27]. The death receptors belong to the tumor
necrosis factor (TNF) receptor superfamily, which includes
Fas, TNFR1, DR3, DR4 (TRAIL-R1), DR5 (TRAIL-R2),
and DR6. Upon ligand binding and trimerization of death
receptors, the intracellular death domain of the death
receptors recruits adapter proteins such as Fas-associated
death domain (FADD), forming a death-inducing signaling
complex (DISC) which helps recruit procaspase-8 to the
DISC. Caspase-8 is then activated, leading to activation of
the downstream eﬀector caspases such as caspase-3 and -
7. The eﬀector caspases can also be activated by death
receptors indirectly through caspase-8-mediated cleavage of
Bid, which facilitates Bax activation and subsequent release
of cytochome C from the mitochondria. Thus, the Bid
cleavage links the two apoptotic pathways [28]. Cellular
FLICE inhibitory protein (c-FLIP), an inactive homolog
of caspase-8, primarily functions as an inhibitor of the
extrinsic apoptotic pathway by preventing caspase-8 activa-
tion, whereas inhibitors of apoptosis protein (IAPs) such
as survivin mainly suppress the intrinsic apoptotic pathway
by inhibiting caspase-9 as well as caspase-3 activation
(Figure 1).
PPARs, particularly PPARγ, and their ligands play a role
in regulation of both apoptotic pathways. Thus, this review
will speciﬁcally focus on the role of PPARγ and its ligands in
regulation of tumor cell apoptosis. Some of the underlying
mechanisms resulting in apoptosis of tumor cells in PPARγ-
dependent and -independent manners will be highlighted.
2. PPARγ AGONISTS INDUCE APOPTOSIS OF
CANCER CELLS
PPARγ agonists (e.g., TZDs) have been shown to induce
apoptosis in a variety of cancer cells including lymphoma,
multiple myeloma, bladder, gastric, esophageal, pancreatic,
hepatoma, colon, breast, brain, and lung cancer cells [8, 12,
29–39].However,many oftheunderlying mechanisms ofthe
apoptotic properties of TZDs remain unknown. In general,
this induction of apoptosis is PPARγ-dependent and/or -
independent depending on cell types or ligands (Table 1).
2.1. PPARγ-dependentapoptosis
In thyroid cancer cell lines, it has been shown that the
expression of PPARγ correlates with the sensitivity of
troglitazone and 15d-PGJ2 to cell death. Thyroid cancer cells
that did not express PPARγ showed no growth inhibitionH. A. Elrod and S.-Y. Sun 3
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Figure 1:SchemaforbasicapoptoticsignalingpathwaysandpossiblemechanismsunderlyingPPARγ ligand-inducedapoptosis.Ligationofdeath
ligands (e.g., TRAIL) with their receptors (e.g., DR5) results in formation of the death-inducing signaling complex (DISC), in which pro-
caspase-8 will be recruited through the death adaptor protein FADD and cleaved to generate activated caspase-8. This process is inhibited by
c-FLIP. Certain stress signals (e.g., DNA damage) can target mitochondria and induce cytochrome C release from the mitochondria into the
cytosol leading to caspase-9 activation by forming an apoptosome via binding to Apaf-1. Both caspase-8 and caspase-9 activate downstream
procaspase-3, -6, and -7, leading to cleavages of their target death proteins such as PARP. In addition, truncated Bid (tBid), activated by
caspase-8 via cleavage, facilitates insertion of Bax into the mitochondrial membrane leading to cytochrome C release. Therefore, tBid may
serve as a link between the extrinsic and intrinsic apoptotic pathways. Inhibitors of apoptosis proteins (IAPs) such as survivin can bind to
activated caspase-9 and prevent its action on eﬀector caspases, whereas SMAC/DIABLO binds to IAPs, leaving caspase-9 free to activate the
eﬀector caspases. PPARγ ligands may induce apoptosis through induction of DR5 and/or downregulation of c-FLIP and/or survivin.
after treatment with troglitazone and 15d-PGJ2 compared
with thyroid cancer cells that did express PPARγ and were
sensitive to growth inhibition by troglitazone and 15d-PGJ2,
suggesting PPARγ-dependent growth inhibition. Growth
inhibition by troglitazone was due to apoptosis as was seen
by DNA laddering [9]. Another study in thyroid cancer cell
lines also implicates PPARγ as an important target. In this
study, ciglitazone was eﬀective in reducing the growth of
thyroid cancer cells that expressed PPARγ,b u th a dn oe ﬀect
in reducing growth in a thyroid cancer cell line that do not
express PPARγ [10]. After introduction of wild-type PPARγ
into the PPARγ-deﬁcient cells, these cells became responsive
to ciglitazone. Moreover, overexpression of PPARγ inthyroid
cancer cells signiﬁcantly increased apoptosis compared to
cells transfected with empty vector or with a vector carrying
a mutated nonfunctional PPARγ cDNA [10]. Collectively,
it appears that the presence of PPARγ at least partly
contributes to the induction of apoptosis by PPARγ ligands
in thyroid cancer. The recent ﬁndings from a transgenic
mouse study [11] may provide an explanation for why
thyroid cancer is susceptible to treatment with PPARγ
agonists. Mice harboring a knockin dominant negative
mutant thyroid hormone receptor β (TRβPV/PV mouse)
spontaneously develop follicular thyroid carcinoma similar
to human thyroid cancer. Using the oﬀspring from the cross
of TRβPV/+ and PPARγ+/− mice, Kato et al. [11]f o u n d
that thyroid carcinogenesis progressed signiﬁcantly faster in
TRβPV/PV mice with PPARγ insuﬃciency from increased
cell proliferation and reduced apoptosis. Reduced PPARγ
protein activated the NF-κB signaling pathway, resulting in
the activation of cyclin D1 and repression of critical genes
involved in apoptosis. Treatment of TRβPV/PV mice with
aP P A R γ agonist, rosiglitazone, delayed the progression of
thyroid carcinogenesis by decreasing cell proliferation and
activating apoptosis. These results suggest that PPARγ is a
critical modiﬁer in thyroid carcinogenesis.
Othermolecularmediatorsofapoptosishavebeenexam-
ined in PPARγ-dependent models. In thyroid cancer cells,4 PPAR Research
troglitazone increased c-Myc expression without changing
the expression of Bcl-2 or Bax [9]. In contrast, in colon can-
cercells,both troglitazoneand15d-PGJ2 havebeen shown to
downregulate c-Myc expression [12]. Thus, whether c-Myc
is involved in mediating PPARγ agonist-induced apoptosis
needs further investigation.
In colon and lung cancer cells, troglitazone was reported
to increase the expression of growth arrest and DNA-
damage inducible 153 (GADD153) [12, 13], a key apoptosis-
regulated gene particularly involved in endoplasmic retic-
ulum (ER) stress-induced apoptosis [40]. Further analysis
revealed that troglitazone did not stimulate GADD153
mRNA levels in undiﬀerentiated 3T3-L1 cells lacking PPARγ
expression, whereas its induction was clearly observed in
diﬀerentiated adipocytes expressing PPARγ, suggesting the
importance of PPARγ in troglitazone-induced GADD153
expression. In lung cancer cells, inhibition of GADD153
gene expression by an antisense phosphorothionate oligonu-
cleotide attenuated the troglitazone-induced growth inhibi-
tion [13]. These ﬁndings collectively suggest that GADD153
might be a candidate factor implicated in TZD-induced
growth inhibition and apoptosis.
Several studies have demonstrated the importance of
ERK and its regulated genes in PPARγ agonist-induced
apoptosis [14–16, 41]. In human lung cancer cells, trogli-
tazone induced apoptosis as well as PPARγ and ERK1/2
accumulationinthenucleus.BothPPARγ siRNAandU0126,
a speciﬁc inhibitor of ERK1/2, blocked these eﬀects of
troglitazone, suggesting that troglitazone-induced apoptosis
is PPARγ- and ERK1/2-dependent. Moreover, inhibition of
ERK1/2 by U0126 also signiﬁcantly decreased the levels
of PPARγ, suggesting a positive crosstalk between PPARγ
and ERK1/2 or an autoregulatory feedback mechanism to
amplify the eﬀect of ERK1/2 on cell growth arrest and
apoptosis [16].
Proline oxidase (POX) is a redox enzyme localized in
the mitochondrial inner membrane and functions as a p53-
induced gene that can mediate apoptosis through generation
ofreactiveoxygenspecies(ROS)[17].Arecentstudyincolon
cancer cells showed that troglitazone enhanced the binding
of PPARγ to PPRE in the POX promoter, activated the
POX promoter, and increased endogenous POX expression.
Blocking of PPARγ activation either by the antagonist
GW9662 or deletion of the PPAR-responsive element in the
POX promoter only partially decreased the POX promoter
activation in response to troglitazone, suggesting also the
involvement of PPARγ-independent mechanisms. Further,
troglitazone induced p53 protein expression in HCT116
cells, which may be the possible mechanism for PPARγ-
independent POX activation, since POX has been shown
to be a downstream mediator in p53-induced apoptosis. In
HCT15 cells, with both mutant p53 and mutant PPARγ,
troglitazone did not activate POX, whereas it did in HT29
cells,withamutantp53andwildtypePPARγ,indicatingthat
both PPARγ-dependent and -independent mechanisms are
involved in the troglitazone-induced POX expression [17].
Thus,thisstudysuggeststhattroglitazone-inducedapoptosis
involves targeting POX gene expression for generation of
ROS.
2.2. PPARγ-independentapoptosis
To help discern the PPARγ-dependent and -independent
properties of TZDs, TZD derivatives lacking PPARγ activity
were developed. These derivatives have a double bond
adjoining the terminal thiazolidine-2,4-dione ring which
abolishes ligand binding to PPARγ [42]. Shiau et al. [18]
showed that the pioglitazone, troglitazone, and ciglitazone
derivatives (Δ2-PG, Δ2-TG, Δ2-CG) were unable to activate
PPARγ compared to pioglitazone, troglitazone, and ciglita-
zone which showed signiﬁcant activation of PPARγ. When
troglitazone and Δ2-TG were tested for growth inhibition
in two prostate cancer cell lines: one cell line expressing
high levels of PPARγ (PC-3) and one deﬁcient of PPARγ
expression (LNCaP), the LNCaP cells were more sensitive to
troglitazone compared to PC-3 cells despite being deﬁcient
in PPARγ.A sw e l l ,Δ2-TG which cannot activate PPARγ
was more eﬀective than troglitazone in suppressing growth
in both PC-3 and LNCaP cells. Both troglitazone and Δ2-
TG induced cytochome C release and DNA fragmentation
in these cells, attributing the growth inhibition to apoptosis.
These results suggest that TZDs can induce apoptosis inde-
pendent of PPARγ activation. The induction of apoptosis
in this study appears to be partly due to the inhibition of
the antiapoptotic function of Bcl-2 and Bcl-XL. It is thought
that Bcl-2 and Bcl-xL sequester proapoptotic molecules such
as Bax and Bak through heterodimerization through BH3
domain binding which inhibits the proapoptotic function of
Bax and Bak [43, 44]. Both troglitazone and Δ2-TG reduced
the association of Bak with Bcl-2 and Bcl-XL causing the
cells to undergo apoptosis as shown by cytochrome C release
and caspase-9 activation. Moreover, Bcl-XL overexpression
protected LNCaP cells from troglitazone- and Δ2-TG-
induced apoptosis [18]. Collectively, these results show that
PPARγ ligands trigger apoptosis independent of PPARγ and
primarilytargetactivationoftheintrinsicapoptoticpathway,
at least in the tested prostate cancer cells.
It was shown that 15d-PGJ2, but not rosiglitazone
and ciglitazone, induced apoptosis in oral squamous cell
carcinoma cells, suggesting that 15d-PGJ2 is acting through
pathways other than activation of PPARγ. In this study,
the apoptotic eﬀect of 15d-PGJ2 was associated with down-
regulation of the oncogene Stat3 which was not seen with
rosiglitazone or ciglitazone [19]. Similarly, in bladder and
prostate cancer cells, 15d-PGJ2 and troglitazone inhibited
cell growth but rosiglitazone and pioglitazone had no eﬀect
on growth inhibition. 15d-PGJ2 inhibited cell growth by
induction of apoptosis, while troglitazone induced cell cycle
arrest [20]. Thus, the induction of apoptosis can also be
selective for certain PPARγ ligands.
Other mediators of apoptosis in PPARγ ligand-induced
cell death include the early growth response-1 (EGR-1)
transcription factor. EGR-1 has been linked to apoptosis
and shown to be activated by ERK. In colon cancer cells,
EGR-1 was induced dramatically by troglitazone but not
by other PPARγ ligands [14]. Inhibition of ERK phos-
phorylation abolished EGR-1 induction by troglitazone,
suggesting an ERK-dependent induction of EGR-1. Given
that troglitazone-induced apoptosis is accompanied by theH. A. Elrod and S.-Y. Sun 5
biosynthesis of EGR-1, these results suggest that PPARγ-
independent EGR-1 induction is a unique property of trogli-
tazone compared with other PPARγ ligands and may play an
important role in troglitazone-induced apoptosis [14]. One
of the EGR-1-regulated genes is proapoptotic nonsteroidal
anti-inﬂammatory drug (NSAID)-activated gene (NAG-1)
[15]. A recent study has demonstrated that the novel TZD
derivative MCC-555 exerts a PPARγ-independent upregula-
tion of NAG-1. Moreover, NAG-1 induction contributes to
MCC-555-induced apoptosis as downregulation of NAG-1
by siRNA suppressed MCC-555-induced apoptosis [41]. As
well, NAG-1 induction was also observed in colon cancer
cellstreatedwithtroglitazoneor15d-PGJ2 [15].Importantly,
both agents induce NAG-1 expression through an EGR-1-
dependent mechanism. However, troglitazone, but not 15d-
PGJ2, increases EGR-1 binding to the EGR-1 binding site
located within region -73 to -51 of the NAG-1 promoter; this
eﬀect has an important role in the transactivation of TGZ-
induced NAG-1 expression. The eﬀect of 15d-PGJ2 is proba-
bly PPARγ-dependent because a PPARγ antagonist inhibited
the 15d-PGJ2-induced expression of NAG-1, whereas TGZ-
induced NAG-1 expression was not inhibited by the PPARγ
antagonist [15].
Multiple myeloma and Burkitt lymphoma cells express
constitutively active NF-κB. 15d-PGJ2 was reported to sup-
press constitutive NF-κB activity and potently induce apop-
tosisinbothtypesofB-cellmalignancies.NF-κBinhibitionis
accompanied by rapid downregulation of NF-κB-dependent
antiapoptotic gene products, including cellular inhibitor-of-
apoptosis protein 1 (cIAP-1), cIAP-2, X-chromosome-linked
inhibitor-of-apoptosis protein (XIAP), and c-FLIP. These
eﬀects were mimicked by the proteasome inhibitor MG-132,
but not by troglitazone, suggesting that 15d-PGJ2-induced
apoptosisisindependentofPPARγ [21].Thus,theinhibition
of NF-κB may play a major role in the proapoptotic activity
of 15d-PGJ2 in aggressive B-cell malignancies characterized
by aberrant regulation of NF-κB. Another study in MCF7
breast cancer cells has shown that both PPARγ and p53 are
involved in rosiglitazone-induced apoptosis. However, the
NF-κB sequence in the p53 promoter region is required for
rosiglitazone to increase p53 transcription in this study [22].
3. PPAR AGONISTS AUGMENT DEATH
RECEPTOR-INDUCED APOPTOSIS
Apoptosis induced by death receptors can be initiated
through binding of death receptor ligands such as TRAIL
or Fas ligand. PPARγ ligands can increase death receptor
expression and augment death receptor-induced apoptosis.
The linkage between PPARγ and TRAIL/death receptor-
induced apoptosis came from the early work showing that
the PPARγ ligand pioglitazone enhances TRAIL-induced
apoptosis through induction of p21 (WAF1) [45, 46].
Subsequently, there are multiple studies demonstrating
that diﬀerent PPARγ ligands have the ability to enhance
TRAIL-induced apoptosis in various types of cancer cells
both in vitro and in vivo [34, 47–51]. The majority of
the studies using various approaches including PPARγ
antagonists, PPARγ siRNA or dominant-negative PPARγ
mutants conclude that PPARγ ligands enhance TRAIL/death
receptor-induced apoptosis through PPARγ-independent
mechanisms [34, 47–49]( Table 2).
Among these studies, Kim et al. [50] ﬁrst reported their
important ﬁndings that a variety of natural and synthetic lig-
andsofPPARγ including15d-PGJ2,ciglitazone,troglitazone,
and the triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-
oic acid (CDDO) selectively reduce the levels of c-FLIP, and
hence sensitize tumor but not normal cells to apoptosis
induction by TRAIL. Both PPARγ agonists and antagonists
displayed these eﬀects, regardless of the levels of PPARγ
expression and even in the presence of a PPARγ dominant-
negative mutant, indicating a PPARγ-independent mecha-
nism. Importantly, PPARγ agonists induced ubiquitination
and proteasome-dependent degradation of c-FLIP, without
concomitant reductions in c-FLIP mRNA, thus demonstrat-
ing a mechanism by which PPARγ agonists decrease c-
FLIP through facilitating ubiquitin/proteasome-dependent
c-FLIP degradation.
Our group has shown that PPARγ agonists including
ciglitazone, troglitazone, and GW1929 induce the expression
of death receptor 5 (DR5) including increasing the cell
surface distribution of DR5, reducing the levels of c-FLIP,
and enhancing TRAIL-induced apoptosis in human lung
cancer cells [34]. When c-FLIP was overexpressed or DR5
was silenced, PPARγ ligands showed diminished ability to
enhanceTRAIL-inducedapoptosis,indicatingthatbothDR5
induction and c-FLIP downregulation are two critical events
accounting for enhancement of TRAIL-induced apoptosis
by PPARγ ligands. Moreover, we have shown that the
modulation of DR5 and c-FLIP expression is independent of
PPARγ because the use of a PPARγ antagonist and silencing
of PPARγ did not eﬀect the ability of the PPARγ ligands to
induce DR5 or downregulate c-FLIP [34].
Consistently, 15d-PGJ2 has also been shown to induce
DR5 expression and augment TRAIL-induced apoptosis in
Jurkat leukemia cells and PC-3 prostate cancer cells. This
induction of DR5 by 15d-PGJ2 occurs posttranscriptionally
through increasing DR5 mRNA stability, which is inde-
pendent of PPARγ activation because two other PPARγ
agonists pioglitazone and rosiglitazone did not upregulate
DR5 expression and pretreatment with GW9662, a PPARγ
inhibitor did not block the induction of DR5 by 15d-
PGJ2 [47]. As well, DR5 upregulation contributes to the
sensitization of TRAIL-induced apoptosis by 15d-PGJ2 since
the knockdown of DR5 using DR5 siRNA decreased apop-
tosis induced by the combination of TRAIL and 15d-PGJ2
compared to control cells [47].
In renal cancer cells, rosiglitazone, in addition to down-
regulating c-FLIP expression, also increases DR5 expression
at the mRNA level [49]. The use of a DR5/Fc chimeric
protein or DR5 siRNA attenuated rosiglitazone and TRAIL-
inducedapoptosis,indicatingacriticalroleofDR5induction
in this death process. Interestingly, rosiglitazone induced the
generation of ROS, whereas cotreatment with glutathione,
which can scavenge ROS, prevented ROS generation,
DR5 upregulation, and enhancement of TRAIL-induced
apoptosis by rosiglitazone, suggesting that ROS-mediated6 PPAR Research
Table 2: Combination of anticancer drugs with PPARγ ligands enhances tumor cell death.
PPARγ agonist + antitumor
agent PPARγ Tumor type Molecular mediator(s) of
apoptosis Reference
Troglitazone or ciglitazone
or GW1929 + TRAIL Independent Lung DR5, c-FLIP [34]
15d-PGJ2 + TRAIL Independent Leukemia, prostate DR5 [47]
Troglitazone + TRAIL Independent Glioblastoma,
neuroblastoma c-FLIP, survivin, DR5 [52]
Rosiglitazone + TRAIL Independent Renal, glioma, breast,
prostate ROS, DR5, c-FLIP [49]
15d-PGJ2 or ciglitazone or
troglitazone or CDDO or
CDDO-Me + TRAIL
Independent Prostate, ovarian, colon c-FLIP [50]
Troglitazone + TRAIL or
troglitazone + etoposide or
paclitaxel
Independent Glioma PTP1B, STAT3, c-FLIP, Bcl-2 [53]
15d-PGJ2 + MK886
Dependent Lung PPARγ,R X R α
[54]
15d-PGJ2 + Indomethacin
Ciglitazone + MK886 + 13-
cis-retinoic acid
Rosiglitazone + LG100268
or all transretinoic acid Dependent and
independent
Leukemia, lymphoma,
myeloma Bcl-2, caspase-9
[55]
15d-PGJ2 +LG100268orall
trans-retinoic acid
CDDO + LG100268 or all
transretinoic acid
Rosiglitazone + carboplatin Dependent Lung, ovarian, colon MT1H, MT1X, MTIIA [56]
TZD18 + imatinib Independent Leukemia Bax, NF-κB[ 57, 58]
RS5444 + paclitaxel Dependent Thyroid p21WAF1/CIP1 [59]
15dPGJ2 + docetaxel Independent Lung Bcl-2, BAD, cyclin D1, p53 [60]
transcriptional activation of DR5 is important for sensitiza-
tion of renal cancer cells to TRAIL-induced apoptosis [49].
As well, glioblastoma and neuroblastoma cells can be
sensitized to TRAIL-induced apoptosis by troglitazone [51].
In addition to upregulation of DR5 and reduction of c-
FLIP, troglitazone downregulated survivin levels in these
cells, all of which may explain the synergy observed with
troglitazone and TRAIL treatment. Importantly, normal
astrocytes did not become sensitive to TRAIL-induced
apoptosis when treated with troglitazone, suggesting lim-
ited toxicity to normal tissues with this treatment [51].
Downregulation of survivin by PPARγ ligands was also
observed in breast cancer cells; this event contributes to
enhancement of TRAIL-induced apoptosis because enforced
expression of ectopic survivin partially protected cells from
troglitazone/TRAIL-induced apoptosis. Diﬀerent from other
studies, this study did not ﬁnd that troglitazone altered the
levels of the key proteins in the death receptor-mediate
apoptotic pathway including DR4, DR5, and c-FLIP. Instead,
they found that troglitazone decreased cyclin D3 levels
through inducing ubiqutin/proteasome-mediated protein
degradation. Importantly, cyclin D3 downregulation is asso-
ciated with troglitazone-induced survivin reduction and
enhancement of TRAIL-induced apoptosis in human breast
cancer cells as silencing of cyclin D3 reduced the levels
of survivin and promoted TRAIL-induced apoptosis [48].
Currently, it is unclear how cyclin D3 regulates survivin
expression.
In human glioma cells, it has been shown that trogli-
tazone activates protein-tyrosine phosphatase-1B (PTP-1B),
which subsequently reduces phosphotyrosine 705 STAT3
(pY705-STAT3) via a PPARγ-independent pathway [53].
Reduction of pY705-STAT3 in glioma cells caused down-
regulation of c-FLIP and Bcl-2. When given in combination
with TRAIL or caspase-dependent chemotherapeutic agents,
such as etoposide and paclitaxel, troglitazone exhibited a
synergistic eﬀect by facilitating caspase-8 and -9 activities.
Thus, it appears that PTP-1B plays a critical role in the
downregulation of activated STAT3, as well as c-FLIP and
Bcl-2[53].However,itisalsonotclearhowPTP-1Bregulates
the expression of c-FLIP and Bcl-2.
Although PPARγ agonists downregulate c-FLIP through
promoting its degradation, the detailed mechanisms by
which PPARγ agonists trigger ubiquitin/proteasome-depen-
dent degradation of c-FLIP are unknown. Moreover, the
mechanisms underlying PPARγ agonist-induced upregula-
tion of DR5 expression have not been addressed as well.
Nonetheless, the sensitization of TRAIL-induced death by
PPARγ agonists may have relevant clinical implications as
TRAIL is currently being tested in clinical trials for cancer.H. A. Elrod and S.-Y. Sun 7
Identiﬁcation of tumors that can overcome TRAIL resistance
by treatment with PPARγ agonists will enhance tumor
speciﬁc targeting by TRAIL and reduce toxicity of normal
tissues as TRAIL has been shown to induce death in tumor
cells while sparing normal cells.
PPARγ agonists have also been shown to eﬀect Fas-
mediated apoptosis. In HT-29 colon cancer cells, there was
a synergistic eﬀect on induction of apoptosis when the anti-
Fas agonistic antibody, CH11, was combined with 15d-PGJ2
orciglitazone[61].Aswell,rosiglitazonesensitizedthebreast
cancer cell line, MDA-MB-231, to the antitumor eﬀects of
CH11 as well as TNF-α [62]. In uterine leiomyoma cells,
ciglitazone downregulated the antiapoptotic protein Bcl-2
and upregulated Bax and Fas while enhancing PARP cleavage
and caspase-8 activation, suggesting that ciglitazone induces
apoptosis in a Fas- and caspase-dependent mechanism [63].
4. PPARγ AGONISTS IN COMBINATION WITH OTHER
ANTICANCER AGENTS ENHANCE APOPTOSIS
Combination therapy regimens are eﬀective in the clinical
treatment of various cancers. Many studies have shown
that combining PPARγ agonists with anticancer agents can
further sensitize tumor cells to apoptosis (Table 2). As we
continue to elucidate the molecular mechanisms of PPARγ
in the regulation of cancer formation and development,
combining PPARγ agonists with other targeted anticancer
agents may be an eﬀective strategy for chemoprevention and
treatment of various cancers.
One such combination involves the 5-lipoxygenase in-
hibitor MK866. MK866 blocks the 5-lipoxygenase pathway
of arachidonic acid metabolism, increases the expression
of PPARα and PPARγ in breast cancer cells, and induces
apoptosis [64]. As well, in lung cancer cells, MK886 in-
creased PPARγ reporter activity. The combination of MK886
with 15d-PGJ2 generated greater growth-inhibitory eﬀects
including apoptosis than each single agent alone in A549
lung cancer cells [54]. Moreover, MK866 increased the
expression of RXRα whose heterodimerization with PPARγ
is thought to be necessary for the proapoptotic eﬀect of
PPARγ. When MK866 was combined with ciglitazone and
the RXR agonist, 13-cis-retinoic acid, there was a superaddi-
tive growth inhibitory eﬀect compared to each drug alone
[54]. These results suggest that the induction of PPARγ
and RXRα by MK866 sensitizes tumor cells to apoptosis
by PPARγ ligands or retinoids. In leukemia, lymphoma,
and myeloma cells, exposure to rosiglitazone, 15d-PGJ2,o r
CDDO in combination with the RXR agonist, LG100268,
or the retinoic acid receptor (RAR) agonist, all transretinoic
acid, augmented the growth-inhibitory eﬀects in these cells
[55]. In agreement, treatment of breast cancer cells with
another RXR selective ligand, AGN194204, and the PPARγ
ligand γ-linolenic acid showed an additive growth inhibitory
response [65]. Thus, combining retinoids with PPAR ligands
may prove to be a successful treatment in some cancers. This
approach may be useful in the clinic as lower doses of each
drug can be used to inhibit growth and a more optimal
therapeutic index can be achieved.
Other drug combinations that show synergy with PPARγ
ligands include the platinum-based drugs. The combination
of rosiglitazone with carboplatin in lung, ovarian, and
colon cancer models showed a synergistic inhibition of
growth. These results are PPARγ-dependent as a non-TZD
PPARγ ligand was also able to enhance growth inhibition
when combined with carboplatin, and the PPARγ antago-
nist GW9662 signiﬁcantly reduced the synergistic eﬀect of
rosiglitazone and carboplatin [56]. This synergy is related
to the metallothioneins which are heavy metal binding
proteins that play a role in platinum drug resistance. Rosigli-
tazone reduces metallothionein gene expression through a
PPARγ-dependent mechanism as treatment with the PPARγ
antagonist GW9662 abrogated metallothionein reduction by
rosiglitazone and the non-TZD PPARγ agonist GW1929 was
also able to reduce metallothionein expression. Moreover,
overexpression of the metallothionein MT1H reduced the
synergistic eﬀect of rosiglitazone and carboplatin. Therefore,
it appears that the downregulation of metallothioneins con-
tributes to the synergism of PPARγ ligands and carboplatin.
This synergistic eﬀect of the combination of rosiglitazone
and carboplatin was also observed in vivo in xenograft
models of lung and ovarian cancer as well as a carcinogen-
induced model of colon cancer [56]. Platinum-based drugs
arecurrentlybeingusedintheclinictotreatlungandovarian
cancer, therefore, the use of PPARγ ligands to enhance the
eﬃcacy of platinum drugs in the treatment of these cancers
would be a great advancement in treating these two deadly
diseases.
Ad u a lP P A R α/γ ligand, TZD18, can induce apoptosis in
adult lymphocytic leukemia and chronic myeloid leukemia
cell lines [57, 58]. When TZD18 was combined with the
bcr-abl tyrosine kinase inhibitor, imatinib, in these cell
lines, there was enhanced growth inhibition. Treatment
of leukemia patients with imatinib has been a successful
therapy, however resistance to imatinib is a problem. These
data suggest that combining TZD18 with imatinib is a
potential therapy for treating imatinib resistant disease.
In these studies, the growth inhibitory eﬀects of TZD18
appeared to be independent of PPARα or PPARγ [57, 58].
A common mutation found in anaplastic thyroid cancer
is a PAX8/PPARγrearrangement which results in down regu-
lation of PPARγ, suggesting that PPARγ may be a tumor
suppressor gene in this type of cancer [59]. In addition,
the fusion protein, PAX8-PPARγ, resulting from this rear-
rangement can act as a dominant negative inhibitor of wild-
type PPARγ [66]. Treatment with the novel PPARγ agonist
RS5444 in anaplastic thyroid cancer cells lines resulted in
growth inhibition and PPARγ activation. When RS5444 was
combinedwithpaclitaxel,astandardtreatmentforanaplastic
thyroid cancer, enhanced apoptosis-inducing eﬀects were
observed [59]. Similarly, the combination of a PPARγ
agonist and docetaxel also exerted enhanced apoptosis-
inducing and antitumor eﬀects in human lung cancer cells.
In addition, 15d-PGJ2 combined with docetaxel signiﬁcantly
reduced tumor volume compared with control, 15d-PGJ2,
or docetaxel alone in both A549 and H460 xenografts.
This combination showed a signiﬁcant increase in apoptosis
associated with inhibition of Bcl-2 and cyclin D1 expression8 PPAR Research
and overexpression of caspase-3 and p53 pathway genes.
However, enhanced expression of caspase 3 and inhibition of
cyclin D1 by the combination was not reversed by GW9662,
thus suggesting a possible PPARγ-independent mechanism
underlying enhanced apoptosis-inducing and antitumor
eﬀects by the combination of 15d-PGJ2 and docetaxel [60].
5. PPARγ ANTAGONISTS EXERT
APOPTOSIS-INDUCING EFFECTS
Although most of the antitumor eﬀects of PPARγ ligands
are attributed to PPARγ agonists, there is evidence that
PPARγ antagonists can have antiproliferative and apoptotic
eﬀects on tumor cells. In one study, two PPARγ antagonists,
T0070907 and GW9662, were tested in a panel of cancer cell
lines and were able to inhibit cell growth and induce apop-
tosis. Combining the PPARγ agonist, pioglitazone, with the
PPARγ antagonists T0070907 or GW9662 actually increased
growth inhibition in a colon cancer cell line compared to
each agent alone [67]. In breast cancer cells, the PPARγ
antagonist GW9662 inhibited growth and also surprisingly
enhanced rosiglitazone-induced growth inhibition [68]. The
eﬀects of this enhanced growth inhibition appeared to
be independent of PPARγ activity as the combination of
GW9662 and rosiglitazone did not result in activation of
PPARγ as compared to rosiglitazone alone which did activate
PPARγ [68]. How the combination of PPARγ agonists and
antagonists can enhance tumor growth inhibition needs
further investigation.
Human primary squamous cellcarcinoma, lymph node
metastasis, and squamous cell carcinoma cell lines express
high levels of PPARγ [69]. The speciﬁc PPARγ antago-
nists T0070907, GW9662, and BADGE, but not agonists
(i.e., pioglitazone and rosiglitazone) induced apoptosis in
squamous cell carcinoma cell lines by interfering with
adhesion to the extracellular matrix and disrupting survival
signals, and thus inducing anoikis. Furthermore, the PPARγ
antagonists strongly inhibited the invasion of squamous
cell carcinomas.These results imply a potentially important
and novel role for the inhibition of PPARγ function via
the use of speciﬁc antagonists in the treatment of oral
squamous cell carcinoma and the prevention of tumor
invasion and metastasis [69]. Similarly, these antagonists
also induced apoptosis in colorectal cancer cells as well as
altered cell morphology which was linked to alterations in
microtubules. The PPARγ antagonists reduced the levels of α
and β tubulin which prevented microtubule formation. This
mechanismisuniquefromtheknownantimicrotubuledrugs
for the treatment of cancer such as the taxanes which alter
microtubule polymerization. These data suggest that PPARγ
antagonists may be used as cancer therapy particularly in
cancers that are not responsive to antimicrotubule therapy
[70].
In contradiction to data suggesting that activation of
PPARγ can reduce tumor growth, treatment with PPARγ
ligands increased the number of colon tumors in the Min
mouse model of familial adenomatous polyposis [71, 72]. In
this model, PPARγ m a yb ep l a y i n gar o l ei nt u m o rp r o m o -
tion. Thus, it appears that activation or inhibition of PPARγ
can have dual roles in tumorigenesis depending on the type
of cancer models examined. Determining the mechanisms of
PPARγ ligands in cancer either dependent or independent of
PPARγ action will be critical to understanding how to best
target tumor cells for eﬀective therapy.
6. ACTIVATION OF PPARγ AS A MECHANISM
FOR CERTAIN ANTICANCER AGENTS TO
INDUCE APOPTOSIS
In addition to PPARγ ligands, certain antitumor agents
induce apoptosis through activation of endogenous PPARγ.
It was reported that the NSAID, sulindac, induced apop-
tosis, and upregulated PPARγ expression in oral squamous
carcinoma cells [73]. When PPARγ was silenced with
PPARγ antisense oligonucleotides, sulindac lost its growth-
inhibitory eﬀects compared to control cells transfected with
PPARγ sense oligonucleotides in which signiﬁcant growth
inhibition was observed. Therefore, PPARγ is an important
mediator of cell growth induced by sulindac [73]. Similarly,
β-carotene was shown to induce apoptosis and increase
PPARγ expression at both mRNA and protein levels in
MCF-7 breast cancer cells. The presence of the PPARγ
antagonist GW9662 partially attenuated β-carotene-induced
cell death, thus suggesting that PPARγ is involved in β-
carotene-induced apoptosis in this cell line [74].
Butyrateisahistonedeacetylaseinhibitorwiththecapac-
ity to induce apoptosis of cancer cells. Its growth-inhibitory
eﬀects were suggested previously to be dependent on PPARγ
activation [75]. A recent study has shown that stimulation of
cells with butyrate increased PPARγ expression and activity
as well as phospho-p38 MAPK protein levels and caspase-
3 activity. Butyrate-induced upregulation of PPARγ was
abrogated by coincubation with the p38 MAPK inhibitor
SB203580. Treatment of cells with butyrate resulted in both
increased caspase-8 and -9 activity and reduced expression
of XIAP and survivin. Moreover, these eﬀects were almost
completelyabolishedincellsexpressingadominant-negative
PPARγ mutant[76].TheseresultscollectivelysuggestPPARγ
as a key target in the butyrate-induced signaling cascade
leading to apoptosis.
Capsaicin (N-vanillyl-8-methyl-alpha-nonenamide), a
spicy component of hot pepper, is a homovanillic acid
derivative that preferentially induces certain cancer cells
to undergo apoptosis and has a putative role in cancer
chemoprevention. In colon cancer cells, capsaicin induced
apoptotic cell death; this eﬀect was completely blocked by
bisphenolAdiglycidylether,aspeciﬁcPPARγ antagonist,but
not by capsazepine, a speciﬁc antagonist for vanilloid recep-
tor [77]. Thus, it seems that capsaicin-induced apoptotic
cell death in colon cancer cells is associated with the PPARγ
pathway without the involvement of the vanilloid receptor.
Abnormally elevated expression or activation of
cyclooxygenase-2 (COX-2) is often associated with cell
proliferation and transformation. However, increased
numbers of studies have suggested that induction of COX-2
can be proapoptotic [78–81]. In COX-2-mediated apoptosis,
production of prostaglandin D2(PGD2) and 15d-PGJ2
and activation of PPARγ have been considered importantH. A. Elrod and S.-Y. Sun 9
mechanisms. For example, the alkylphospholipid type
antitumor agent ET-18-O-CH3, at the same concentration
ranges that induce apoptosis, induced COX-2 expression in
H-ras transformed human breast epithelial cells (MCF10A-
ras). The addition of a selective COX-2 inhibitor SC-58635
and COX-2 gene knockdown blocked ET-18-O-CH3-
induced apoptosis, suggesting that COX-2 induction by this
drug is causally linked to its apoptosis-inducing activity.
ET-18-O-CH3 treatment resulted in elevated release of
15d-PGJ2 and DNA binding and transcriptional activity of
PPARγ. These data suggest that ET-18-O-CH3 likely induces
COX-2 expression and production of 15d-PGJ2, leading to
induction of apoptosis in MCF10A-ras cells [79].
Inagreement,severalchemotherapeuticsincludingpacli-
taxel, cisplatin, and 5-ﬂuorouracil induced COX-2 expres-
sion and prostaglandin (PG) synthesis, accompanied by a
substantialdecreaseofviabilityandenhancedapoptosis[80].
Cells were signiﬁcantly less sensitive to apoptotic death when
either COX-2 expression or its activity was suppressed by
siRNA or by the selective COX-2 inhibitor NS-398. Exper-
iments performed to clarify how COX-2 leads to apoptosis
revealed a profound proapoptotic action of PGD2 and its
dehydration product, 15d-PGJ2, because chemotherapeutic-
induced apoptosis was prevented by siRNA targeting
lipocalin-type PGD synthase (L-PGDS), which catalyzes the
isomerization of PGH2 to PGD2. Moreover, apoptosis by
chemotherapeutics, PGD2 and 15d-PGJ2 , was suppressed
by the PPARγ antagonist, GW-9662 or PPARγ siRNA.
Collectively, this study suggests that COX-2 induction and
synthesis of L-PGDS-derived PPARγ-activating PGs are a
decisive target by which several chemotherapeutics induce
apoptosis [80]. As well, the novel natural compound,
a cycloanthranilylproline derivative (Fuligocandin B) was
recently reported to sensitize leukemia cells to TRAIL-
induced apoptosis through COX-2-dependent 15d-PGJ2
production. However, the synergy mediated by 15d-PGJ2
works in a PPARγ-independent manner as PPARγ siRNA
failed to block the synergy [82].
These ﬁndings have important clinical impact on the
treatment of cancer patients if this mechanism, particularly
to chemotherapeutic agents, is common in diﬀerent types
of cancer cells. Because NSAIDs possess COX-2-inhibitory
activity and are commonly used by many people including
cancer patients, caution should be taken during cancer
chemotherapy to avoid potentially diminished therapeutic
eﬃcacy due to COX-2 inhibition.
7. CONCLUSIONS
The role of PPARs, particularly PPARγ,i nc a n c e ri sa n
evolving ﬁeld. Understanding of the molecular mechanisms
underlying PPAR-mediated regulation of apoptosis of tumor
cells will continue to expand. Accordingly, targeting PPARs,
especially PPARγ for cancer chemoprevention and therapy
may prove to be very eﬀective and will remain an interesting
research topic. As we continue to address speciﬁc signaling
pathways that lead to cancer, we can further elucidate how
PPARs and their ligands contribute to these pathways and
design eﬀective combinations of therapy that target multiple
steps in the oncogenic process. PPARγ ligands have the
potential to sensitize cancer cells to or overcome resistance
to chemotherapy or other anticancer drug-based therapies.
Thus, exploring mechanism-driven PPARγ ligand-based
combinationregimensforbothcancerchemopreventionand
therapyshouldbethefocusofthisfuturestudy.Speciﬁctypes
oftumorsanduniquetumormicroenvironmentsalsobehave
diﬀerently to PPAR activation or inhibition. Therefore, a
close examination of individual tumor types and their
response to PPAR stimulation will be critical for successful
cancer therapy targeting PPARs, particularly PPARγ.M a n y
studies have revealed that TZDs exert PPARγ-independent
eﬀects on induction of apoptosis in various cancer cells.
Although some of the TZDs are clinically used drugs for
treatment of diabetes with acceptable or manageable side
eﬀects or toxicity, they were not originally developed as
anticancer drugs and hence are not optimal for cancer
treatment. Therefore, it is necessary to use them as lead
compounds for synthesizing analogs as anticancer drugs
that possess better or optimized cancer chemopreventive or
therapeutic eﬃcacy.
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